Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Lindner

Showing results (671-680 of 708) with videos related to

Pageof 71
Sort By:
ESMO Open|April 10, 2026
A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trialG-E Schuebbe, Y Xu, L H Lindner, et al.
Cancers|November 11, 2022
Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV TrialViktor Grünwald, Daniel Pink, Gerlinde Egerer, et al.
Journal of Cancer Research and Clinical Oncology|January 8, 2026
Long-term benefit from high-dose ifosfamide in sarcoma depends on sustained prior control and timely intervention: a machine learning analysisMichael Hoberger, Romy L Zuber, Anton Burkhard-Meier, et al.
Nature Communications|January 31, 2018
Isolated proton bunch acceleration by a petawatt laser pulseP Hilz, T M Ostermayr, A Huebl, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 5, 2026
Initial Clinical Experience with [<sup>177</sup>Lu]Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and DosimetryLisa Glantschnig, Johanna S Enke, Bradley W Schuller, et al.
Oncology and Therapy|June 5, 2026
Machine Learning-Guided Survival Prediction and Treatment Sequencing in Advanced Soft Tissue Sarcoma Beyond Second-Line Therapy: A Retrospective Cohort StudyMichael Hoberger, Dorit Di Gioia, Romy L Zuber, et al.
The New England Journal of Medicine|March 4, 2026
Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid SyndromeAdrian Gottschlich, Veit Bücklein, Karim El-Marouk, et al.
Clinical Kidney Journal|July 2, 2026
Clinical impact of genetic testing in inherited kidney diseasesLea M Merz, Sarah Stopp, Ilona Krey, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|January 11, 2020
Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma - a case reportRolf D Issels, Lars H Lindner, Michael von Bergwelt-Baildon, et al.
JAMA Oncology|February 17, 2018
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical TrialRolf D Issels, Lars H Lindner, Jaap Verweij, et al.
Pageof 71

Showing results (671-680 of 708) with videos related to

Sort By:
Pageof 71
ESMO Open|April 10, 2026
A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trialG-E Schuebbe, Y Xu, L H Lindner, et al.
Cancers|November 11, 2022
Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV TrialViktor Grünwald, Daniel Pink, Gerlinde Egerer, et al.
Journal of Cancer Research and Clinical Oncology|January 8, 2026
Long-term benefit from high-dose ifosfamide in sarcoma depends on sustained prior control and timely intervention: a machine learning analysisMichael Hoberger, Romy L Zuber, Anton Burkhard-Meier, et al.
Nature Communications|January 31, 2018
Isolated proton bunch acceleration by a petawatt laser pulseP Hilz, T M Ostermayr, A Huebl, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 5, 2026
Initial Clinical Experience with [<sup>177</sup>Lu]Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and DosimetryLisa Glantschnig, Johanna S Enke, Bradley W Schuller, et al.
Oncology and Therapy|June 5, 2026
Machine Learning-Guided Survival Prediction and Treatment Sequencing in Advanced Soft Tissue Sarcoma Beyond Second-Line Therapy: A Retrospective Cohort StudyMichael Hoberger, Dorit Di Gioia, Romy L Zuber, et al.
The New England Journal of Medicine|March 4, 2026
Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid SyndromeAdrian Gottschlich, Veit Bücklein, Karim El-Marouk, et al.
Clinical Kidney Journal|July 2, 2026
Clinical impact of genetic testing in inherited kidney diseasesLea M Merz, Sarah Stopp, Ilona Krey, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|January 11, 2020
Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma - a case reportRolf D Issels, Lars H Lindner, Michael von Bergwelt-Baildon, et al.
JAMA Oncology|February 17, 2018
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical TrialRolf D Issels, Lars H Lindner, Jaap Verweij, et al.
Pageof 71